title: Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases.
authors.forename: J
authors.initials: J
authors.lastname: Lübbe
authors.forename: K
authors.initials: K
authors.lastname: Kerl
authors.forename: F
authors.initials: F
authors.lastname: Negro
authors.forename: J-H
authors.initials: JH
authors.lastname: Saurat
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000009:adverse effects; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a